Avalo Therapeutics Inc (AVTX)

Currency in USD
14.175
+0.245(+1.76%)
Real-time Data·
AVTX is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
13.56014.450
52 wk Range
3.39020.720
Key Statistics
Prev. Close
13.93
Open
14.12
Day's Range
13.56-14.45
52 wk Range
3.39-20.72
Volume
621.92K
Average Volume (3m)
536.18K
1-Year Change
76.9663%
Book Value / Share
4.58
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
AVTX Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
37.889
Upside
+167.29%
Members' Sentiments
Bearish
Bullish
ProTips
Analysts anticipate sales decline in the current year

Avalo Therapeutics Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Buy

Avalo Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. Its lead asset includes AVTX-009, a humanized monoclonal antibody that binds to interleukin-1ß, which is in phase 2 clinical trial to treat inflammatory diseases. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Rockville, Maryland.

Compare AVTX to Peers and Sector

Metrics to compare
AVTX
Peers
Sector
Relationship
P/E Ratio
−4.0x−2.6x−0.4x
PEG Ratio
−0.06−0.080.00
Price/Book
3.8x2.6x2.6x
Price / LTM Sales
5,318.6x6.9x3.1x
Upside (Analyst Target)
172.9%161.6%58.8%
Fair Value Upside
Unlock7.0%9.2%Unlock

Analyst Ratings

11 Buy
0 Hold
0 Sell
Ratings:
11 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 37.889
(+167.29% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
H.C. Wainwright
Buy40.00+184.70%25.00Maintain25/03/2026
BTIG
Buy40.00+184.70%-Maintain23/03/2026
Wedbush
Buy29.00+106.41%28.00Maintain23/03/2026
Guggenheim
Buy50.00+255.87%-Maintain23/03/2026
TD Cowen
Buy---Maintain24/02/2026

Earnings

Latest Release
23/03/2026
EPS / Forecast
-0.75 / -1.25
Revenue / Forecast
59K / --
EPS Revisions
Last 90 days

People Also Watch

14.330
CRVS
+6.94%
14.45
OLMA
+7.64%
85.17
RYTM
+10.25%
4.77
FHTX
+7.92%
5.780
XERS
+3.21%

FAQ

What Is the Avalo Therapeutics (AVTX) Share Price Today?

The Avalo Therapeutics stock price today is 14.175 USD.

What Stock Exchange Does Avalo Therapeutics (AVTX) Trade On?

Avalo Therapeutics is listed and trades on the Nasdaq Stock Exchange.

What Is the Ticker (Stock Symbol) for Avalo Therapeutics?

The stock symbol (also called a 'ticker') for Avalo Therapeutics is "AVTX."

What Is the Current Avalo Therapeutics Market Cap?

As of today, Avalo Therapeutics market cap is 320.180M USD.

What Is Avalo Therapeutics's (AVTX) Earnings Per Share (TTM)?

The Avalo Therapeutics EPS is currently -5.840 (Trailing Twelve Months).

Is AVTX a Buy or Sell From a Technical Analyst Perspective?

Based on today's Avalo Therapeutics moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has Avalo Therapeutics Stock Split?

Avalo Therapeutics has split 2 times. (See the AVTX stock split history page for full effective split date and price information.)

How Many Employees Does Avalo Therapeutics Have?

Avalo Therapeutics has 33 employees.

What is the current trading status of Avalo Therapeutics (AVTX)?

As of 31/03/2026, Avalo Therapeutics (AVTX) is trading at a price of 14.175 USD, with a previous close of 13.930 USD. The stock has fluctuated within a day range of 13.560 USD to 14.450 USD, while its 52-week range spans from 3.390 USD to 20.720 USD.

What Is Avalo Therapeutics (AVTX) Price Target According to Analysts?

The average 12-month price target for Avalo Therapeutics is 37.889 USD, with a high estimate of 50 USD and a low estimate of 24 USD. 11 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +167.29% Upside potential.

What Is the AVTX Premarket Price?

AVTX's last pre-market stock price is 13.780 USD. The pre-market share volume is 220.000, and the stock has decreased by -0.150, or -1.080%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.